Document › Details
PeptiDream Inc.. (4/2/15). "Press Release: PeptiDream Announces License of PeptiDream’s Peptide Discovery Platform System (PDPS) Technology to Novartis". Tokyo.
|Organisation||PeptiDream Inc. (JP)|
|Organisation 2||Novartis AG (NYSE: NVS)|
|Product||Peptide Discovery Platform System (PDPS) technology|
|Product 2||peptide-based drug|
|Index term||Novartis–PeptiDream: drug discovery technology, 201504– license non-excl for use of PDPS technology by Novartis|
|Person||Kubota, Kiichi (PeptiDream 201504 CEO)|
PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587) announced today that Swiss-based Novartis has exercised its option under their 2012 Strategic Alliance Agreement to obtain a nonexclusive license to PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the Technology License Agreement, PeptiDream will receive multi-stage upfront technology access payments, and will be eligible to receive development milestones and royalties on future sales of products that arise from use of the PDPS technology.
[Comments from Kiichi Kubota, CEO of PeptiDream Inc.]
“We are delighted with Novartis’s decision to internalize the PDPS technology under our 2012 Strategic Alliance Agreement, and this exercise further validates our PDPS technology as one of the best hit-finding/discovery platforms. The license agreement will significantly contribute to PeptiDream’s revenue both in the short term and has the potential to generate significant revenues long into the future.”
(Ticker Code:4587 TSE Mothers)
<About PeptiDream Inc.>
PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit www.peptidream.com
Patrick C Reid +81-3-5790-9991 (Tokyo)
Record changed: 2017-04-02
More documents for PeptiDream Inc. (JP)
-  PeptiDream Inc.. (4/29/15). "Press Release: PeptiDream Announces Peptide Discovery Collaboration Agreement with Merck & Co., Inc". Tokyo....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)